Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 1
2011 2
2012 1
2015 1
2016 3
2017 1
2018 2
2019 2
2020 2
2021 5
2022 5
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Rubino D, et al. JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224. JAMA. 2021. PMID: 33755728 Free PMC article. Clinical Trial.
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Del Prato S, et al. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. Lancet. 2021. PMID: 34672967 Clinical Trial.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
Low-Dose Cyproterone Acetate Treatment for Transgender Women.
Even Zohar N, Sofer Y, Yaish I, Serebro M, Tordjman K, Greenman Y. Even Zohar N, et al. Among authors: sofer y. J Sex Med. 2021 Jul;18(7):1292-1298. doi: 10.1016/j.jsxm.2021.04.008. Epub 2021 Jun 24. J Sex Med. 2021. PMID: 34176757
Transgender men's preferences when choosing obstetricians and gynecologists.
Lifshitz D, Yaish I, Wagner-Kolasko G, Greenman Y, Sofer Y, Alpern S, Groutz A, Azem F, Amir H. Lifshitz D, et al. Among authors: sofer y. Isr J Health Policy Res. 2022 Feb 11;11(1):12. doi: 10.1186/s13584-022-00522-z. Isr J Health Policy Res. 2022. PMID: 35148780 Free PMC article.
Endocrinology specialty service for inpatients: an unmet growing need.
Osher E, Zohar NE, Yacobi-Bach M, Cantrell D, Serebro M, Sofer Y, Greenman Y, Tordjman K, Stern N. Osher E, et al. Among authors: sofer y. BMC Health Serv Res. 2023 Feb 10;23(1):142. doi: 10.1186/s12913-023-09134-y. BMC Health Serv Res. 2023. PMID: 36759836 Free PMC article.
A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors.
Osher E, Shalabna E, Klausner JM, Greenman Y, Stern N, Shibolet O, Scapa E, Yakir O, Shor DB, Bar-Yishay I, Shamai S, Sofer Y, Lubezky N, Goykhman Y, Lahat G, Wolf I, Pelles S, Aizic A, Blachar A, Geva R. Osher E, et al. Among authors: sofer y. Biomedicines. 2023 Jan 30;11(2):407. doi: 10.3390/biomedicines11020407. Biomedicines. 2023. PMID: 36830943 Free PMC article.
Dysglycemia in non-functioning pancreatic neuroendocrine tumors (NF-PNET): Further insights into an under recognized entity.
Osher E, Geva R, Wolf I, Tordjman K, Klausner J, Sofer Y, Scapa E, Shibolet O, Ben-Ami Shor D, Bar-Yishay I, Lubezky N, Goykhman Y, Lahat G, Yakir O, Pelles S, Aizic A, Blachar A, Stern N, Greenman Y. Osher E, et al. Among authors: sofer y. J Clin Transl Endocrinol. 2023 Aug 17;33:100322. doi: 10.1016/j.jcte.2023.100322. eCollection 2023 Sep. J Clin Transl Endocrinol. 2023. PMID: 37663867 Free PMC article.
28 results